At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Antiplatelets; Small molecules; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 22 Sep 1998 No-Development-Reported for Thrombosis in USA (Unknown route)
- 12 Sep 1995 New profile
- 12 Sep 1995 Preclinical development for Thrombosis in USA (Unknown route)